Shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) were the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 18,661,854 shares, a decrease of 9.9% from the April 15th total of 20,716,430 shares, American Banking News.com reports. Based on an average trading volume of 1,068,926 shares, the short-interest ratio is currently 17.5 days. Approximately 31.5% of the shares of the company are short sold. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) weekly performance is -4.06%. On last trading day company shares ended up $3.07. Analysts mean target price for the company is $7.00. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) distance from 50-day simple moving average (SMA50) is -21.89%.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), announced the appointment of Chris Bowden, M.D., to the newly created position of chief medical officer, where he will oversee global clinical development and regulatory initiatives for Agios. Dr. Bowden, who brings more than 17 years of experience in clinical drug development, including the approval of several cancer medicines, was previously vice president, product development oncology, franchise lead (Signaling Group) at Genentech, Inc., a member of the Roche Group. Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares fell -6.60% in last trading session and ended the day on $31.86. Its return on assets is -31.90%. Agios Pharmaceuticals Inc (NASDAQ:AGIO) quarterly performance is -1.21%.
Genetic Technologies Limited (ADR) (NASDAQ:GENE) announced the completion of a series of transactions with the Company’s largest shareholder, Dr. Mervyn Jacobson (collectively, the “Jacobson Entities”). This arrangement commenced on December 18, 2013 resulting in the disposal of 105,937,500 shares in the Company including 30,000,000 Shares which were transferred (by a special crossing) with parties unrelated arrangements outlined below. As a result, Dr. Jacobson’s interest in the issued capital of the Company was reduced from 23.83% to 5.33%. This assumed no other share transactions in the interim. Genetic Technologies Limited (ADR) (NASDAQ:GENE) shares moved down -5.98% in last trading session and was closed at $1.10, while trading in range of $1.06 – $1.20. Genetic Technologies Limited (ADR) (NASDAQ:GENE) year to date (YTD) performance is -23.08%.
Galena Biopharma Inc (NASDAQ:GALE), a bio pharmaceutical company that is developing as well as commercializing many innovative and targeted oncology treatments which address many major and unmet medical needs in the advancement of cancer care, announced that the Department of Defense will now provide it with funding towards its new clinical-trial with NeuVax in prevention of breast cancer recurrence in the high-risk HER2 3+ patients. This grant, which is a Breast Cancer Research Program Breakthrough Award, has been obtained by Elizabeth A. Mittendorf, M.D., the Associate Professor at the Department of Surgical Oncology, at The University of Texas’ MD Anderson Cancer Center. Galena Biopharma Inc (NASDAQ:GALE) ended the last trading day at $2.10. Company weekly volatility is calculated as 6.61% and price to cash ratio as 4.73. Galena Biopharma Inc (NASDAQ:GALE) showed a negative weekly performance of -11.39%.
Easton Pharmaceuticals Inc (OTCMKTS:EAPH) announces it had provided BMV Medica S.A. de C.V. confirmation of final payment to BMV towards it Mexican initiatives regarding Easton’s Viorra product. Announces new Michigan proposal in its medical marijuana initiatives. Easton Pharmaceuticals Inc (OTCMKTS:EAPH) On last trading day company shares ended up $0.0205.